Cargando…

Design of Effisayil™ 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis

INTRODUCTION: Generalized pustular psoriasis (GPP) is a rare autoinflammatory skin disease characterized by flares of widespread erythema with sterile pustules, and can be relapsing with recurrent flares, or persistent with intermittent flares. Spesolimab, a humanized anti-interleukin-36 (IL-36) rec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morita, Akimichi, Choon, Siew Eng, Bachelez, Hervé, Anadkat, Milan J., Marrakchi, Slaheddine, Zheng, Min, Tsai, Tsen-Fang, Turki, Hamida, Hua, Harry, Rajeswari, Sushmita, Thoma, Christian, Burden, A. David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823166/ https://www.ncbi.nlm.nih.gov/pubmed/36333618 http://dx.doi.org/10.1007/s13555-022-00835-6

Ejemplares similares

Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare
por: Choon, Siew Eng, et al.
Publicado: (2021)

Efficacy and safety of spesolimab in Asian patients with a generalized pustular psoriasis flare: Results from the randomized, double‐blind, placebo‐controlled Effisayil™ 1 study
por: Morita, Akimichi, et al.
Publicado: (2022)

Clinical Characteristics and Outcomes of Generalized Pustular Psoriasis Flares
por: Choon, Siew Eng, et al.
Publicado: (2023)

Efficacy and Safety of Spesolimab in Patients with Generalized Pustular Psoriasis: A Subgroup Analysis of Chinese Patients in the Effisayil 1 Trial
por: Tsai, Tsen-Fang, et al.
Publicado: (2023)

Rapid response of spesolimab in biologics – failure patient with generalized pustular psoriasis flare
por: Jiang, Meng, et al.
Publicado: (2023)

Pathophysiology of Generalized Pustular Psoriasis
por: Marrakchi, Slaheddine, et al.
Publicado: (2022)

Clinical Disease Measures in Generalized Pustular Psoriasis
por: Burden, A. David, et al.
Publicado: (2022)

Spesolimab: First Approval
por: Blair, Hannah A.
Publicado: (2022)

Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study
por: Burden, A. David, et al.
Publicado: (2023)

Commentary on a Clinical Trial of Spesolimab, a Humanized Anti-interleukin-36 Receptor Monoclonal Antibody, in Generalized Pustular Psoriasis
por: Shao, Shuai, et al.
Publicado: (2022)

Correction to: Spesolimab: First Approval
por: Blair, Hannah A.
Publicado: (2022)

Clinical Course and Characteristics of Generalized Pustular Psoriasis
por: Choon, Siew Eng, et al.
Publicado: (2022)

Pustular Psoriasis: The Dawn of a New Era
por: BACHELEZ, Hervé
Publicado: (2020)

Spesolimab use in treatment of pyoderma gangrenosum
por: Guénin, Sophie H., et al.
Publicado: (2023)

A pustular psoriasis flare treated with calcium supplementation
por: Masson, Laure, et al.
Publicado: (2021)

Great imitator with exclusive oral manifestations
por: Hayder, Faten, et al.
Publicado: (2022)

Congenital lamellar ichthyosis in Tunisia is caused by a founder nonsense mutation in the TGM1 gene
por: Louhichi, Nacim, et al.
Publicado: (2012)

Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study
por: Mrowietz, Ulrich, et al.
Publicado: (2021)

Understanding Flares in Patients With Generalized Pustular Psoriasis Documented in US Electronic Health Records
por: Zema, Carla L., et al.
Publicado: (2022)

Tozinameran: Flare-up of generalised pustular psoriasis and systemic capillary leak syndrome: case report
Publicado: (2022)

Characteristics of Patients Experiencing a Flare of Generalized Pustular Psoriasis: A Multicenter Observational Study
por: Bellinato, Francesco, et al.
Publicado: (2023)

Patient characteristics and burden of disease in Japanese patients with generalized pustular psoriasis: Results from the Medical Data Vision claims database
por: Morita, Akimichi, et al.
Publicado: (2021)

Clinical and genetic differences between pustular psoriasis subtypes
por: Twelves, Sophie, et al.
Publicado: (2019)

A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: Case report
por: Onsun, Nahide, et al.
Publicado: (2021)

Response to “New-onset pustular psoriasis in the setting of severe acute respiratory syndrome coronavirus 2 infection causing coronavirus disease 2019”
por: Assan, Florence, et al.
Publicado: (2021)

Ixekizumab 80 mg Every 2 Weeks Treatment Beyond Week 12 for Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis
por: Morita, Akimichi, et al.
Publicado: (2021)

Identification of a novel missense mutation in NIPAL4 gene: First 3D model construction predicted its pathogenicity
por: Laadhar, Sahar, et al.
Publicado: (2019)

Clinical and genetic investigation of ichthyosis in familial and sporadic cases in south of Tunisia: genotype–phenotype correlation
por: Ennouri, Mariem, et al.
Publicado: (2022)

Symptom Experience and Content Validity of the Psoriasis Symptom Scale (PSS) in Patients with Generalized Pustular Psoriasis (GPP)
por: Burden, A. David, et al.
Publicado: (2022)

Loss-of-Function Myeloperoxidase Mutations Are Associated with Increased Neutrophil Counts and Pustular Skin Disease
por: Vergnano, Marta, et al.
Publicado: (2020)

Loss-of-function myeloperoxidase mutations are associated with increased neutrophil counts and pustular skin disease
por: Vergnano, Marta, et al.
Publicado: (2021)

Clinical characteristics and health‐care resource utilization in patients with generalized pustular psoriasis using real‐world evidence from the Japanese Medical Data Center database
por: Okubo, Yukari, et al.
Publicado: (2021)

Assessment of the Pharmacokinetics and Safety of Spesolimab, a Humanised Anti-interleukin-36 Receptor Monoclonal Antibody, in Healthy Non-Japanese and Japanese Subjects: Results from Phase I Clinical Studies
por: Joseph, David, et al.
Publicado: (2022)

Remission einer therapierefraktären generalisierten pustulösen Psoriasis unter dem Interleukin-36-Rezeptor-Inhibitor Spesolimab
por: Müller, Valentina Laura, et al.
Publicado: (2023)

Adalimumab treatment in Japanese patients with generalized pustular psoriasis: Results of an open‐label phase 3 study
por: Morita, Akimichi, et al.
Publicado: (2018)

Unmet Medical Needs in the Treatment and Management of Generalized Pustular Psoriasis Flares: Evidence from a Survey of Corrona Registry Dermatologists
por: Strober, Bruce, et al.
Publicado: (2021)

Efficacy and safety of risankizumab in Japanese patients with generalized pustular psoriasis or erythrodermic psoriasis: Primary analysis and 180‐week follow‐up results from the phase 3, multicenter IMMspire study
por: Yamanaka, Keiichi, et al.
Publicado: (2022)

Thyroid involvement in Chanarin-Dorfman syndrome in adults in the largest series of patients carrying the same founder mutation in ABHD5 gene
por: Louhichi, Nacim, et al.
Publicado: (2019)

Mutations in CERS3 Cause Autosomal Recessive Congenital Ichthyosis in Humans
por: Radner, Franz P. W., et al.
Publicado: (2013)

Correction: Mutations in CERS3 Cause Autosomal Recessive Congenital Ichthyosis in Humans
por: Radner, Franz P. W., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_augdb327ea5nds2b1r0s0rhg43